Natl Toxicol Program Tech Rep Ser. 1996 Aug;383:1-370.
1-Amino-2,4-dibromoanthraquinone is an anthraquinone-derived vat dye, a member of a class of insoluble dyes that are impregnated into textile fibers. Five anthraquinone-derived dyes with representative and diverse structures, as well as the parent chemical, anthraquinone, were selected for NTP Toxicology and Carcinogenesis evaluation. Similar to the benzidine dye initiative, the rationale for selecting these vat dyes was to generate sufficient toxicologic data to permit more reliable predictions of carcinogenicity to be made on other chemicals in this class, thereby eliminating or reducing the need to study every anthraquinone dye. 1-Amino-2,4-dibromoanthraquinone is the last anthraquinone-derived dye in this group to be studied. Groups of male and female F344/N rats and B6C3F1 mice were exposed to 1-amino-2,4-dibromoanthraquinone (87% to 97% pure) for 13 weeks or for 9, 15, or 24 months. Because 1-amino-2,4-dibromoanthraquinone was predicted to be carcinogenic, these studies were designed to evaluate the potential for tumor progression and regression. Absorption and excretion studies were carried out in male F344/N rats. Genetic toxicity was determined in vitro using Salmonella typhimurium and cultured Chinese hamster ovary cells. Extensive chemical analyses were performed to identify and characterize impurities of the 1-amino-2,4-dibromoanthraquinone used in these studies. 13-WEEK STUDY IN RATS: Groups of 10 male and 10 female rats were given 0, 2,500, 5,000, 10,000, 25,000, or 50,000 ppm 1-amino-2,4-dibromoanthraquinone in feed for 13 weeks. These levels correspond to approximately 150 to 3,200 mg 1-amino-2,4-dibromoanthraquinone/kg body weight per day for males and to approximately 170 to 3,200 mg/kg for females. Chemical-related mortality was limited to one male and one female in the 50,000 ppm groups. Final mean body weights and body weight gains of all exposed groups of rats were significantly lower than those of the controls. Feed consumption by all exposed groups was less than that by the controls throughout the study and generally decreased with increasing exposure concentration. Pink-red staining of the fur and tail was observed in all exposed groups. Absolute and relative liver weights of all exposed groups were generally significantly greater than those of the controls. Chemical-related lesions were present in the liver, kidney, and spleen of male and female rats. Nonneoplastic lesions in the liver included foci of hepatocellular alteration, diffuse hepatocellular hypertrophy (cytomegaly), hepatocellular cytoplasmic vacuolation, bile duct hyperplasia, inflammation, and pigmentation. These differences were observed primarily in the 25,000 and 50,000 ppm groups of males and females; the spectrum of proliferative lesions of the bile ducts (hyperplasia, fibrosis, and necrotizing cholangitis) in the 25,000 and 50,000 ppm groups was morphologically consistent with the lesion described as cholangiofibrosis. Pigmentation was present in the renal tubule epithelium of all groups of exposed rats; nuclear enlargement (karyomegaly) was also present in the renal tubule epithelium in some of the exposed rats. Accumulation of hyaline droplets in the cytoplasm of the renal tubule epithelium and tubule lumina was present in 2,500, 5,000, 10,000, and 25,000 ppm males. Incidences of hematopoiesis of the spleen in exposed groups of males and females were increased compared to those in the controls. 13-WEEK STUDY IN MICE: Groups of 10 male and 10 female mice were given 0, 2,500, 5,000, 10,000, 25,000, or 50,000 ppm 1-amino-2,4-dibromoanthraquinone in feed for 13 weeks. These levels correspond to approximately 500 to 10,600 mg 1-amino-2,4-dibromoanthraquinone/kg body weight per day for males and approximately 660 to 11,700 mg/kg per day for females. There was no chemical-related mortality. Feed consumption and final mean body weights of exposed groups were similar to those of the controls. Red staining of the fur was observed in all exposed groups. Absolute and relative liver weights of the exposed groups were greater than those er than those of the controls except for the absolute liver weight of 2,500 ppm males. Absolute and relative kidney weights of 25,000 and 50,000 ppm males were lower than those of the controls. Chemical-related lesions were limited to the livers of males and consisted of pigmentation of hepatocytes at all exposure concentrations and centrilobular hepatocellular hypertrophy at 10,000, 25,000, and 50,000 ppm. Minimal pigment was present in the liver of one female in the 25,000 ppm group and in one female in the 50,000 ppm group. 2-YEAR STUDY IN RATS: Groups of 70 male and 70 female rats were given 0, 5,000, or 10,000 ppm 1-amino-2,4-dibromoanthraquinone in feed for 103 weeks. In addition, groups of 50 male and 50 female rats were given 2,000 ppm 1-amino-2,4-dibromoanthraquinone in feed for 104 weeks. These exposure concentrations were approximately equal to 90, 240, or 490 mg 1-amino-2,4-dibromoanthraquinone/kg body weight for males and 110, 285, or 600 mg/kg for females. Ten animals from each group were evaluated for histopathology at 9 months. Additional groups of 10 animals from the 0 and 10,000 ppm groups were evaluated for histopathology at 15 months. Survival, Body Weights, Feed Consumption, and Clinical Findings In the 2-year study, survival of the 10,000 ppm males and females was significantly lower than that of the controls. Survival of the 2,000 and 5,000 ppm groups was similar to that of the controls. During the last year of the study, the mean body weights of exposed males were 80% to 91% those of controls, and the mean body weights of exposed females were 67% to 84% those of controls. Feed consumption among exposed groups was generally similar, but was less than that by controls. The fur and urine of all exposed male and female groups were discolored. Pathology Findings In the 2-year study, 1-amino-2,4-dibromoanthraquinone was associated with significant chemical-related increases in the incidences of benign and malignant neoplasms in the liver, large intestine, kidney, and urinary bladder of males and females. Chemical-related nonneoplastic proliferative and degenerative lesions occurred in the liver, kidney, urinary bladder, and forestomach of males and females. The incidences of foci of hepatocellular alteration and pigmentation in the liver of males and females were increased at the 9-month interim evaluation, and a hepatocellular adenoma was present in one 5,000 ppm male. At the 15-month interim evaluation, hepatocellular adenoma or carcinoma (combined) occurred in all males and nine females in the 10,000 ppm groups. By the end of the 2-year study, hepatocellular adenoma, carcinoma, cholangioma, or cholangiocarcinoma were observed in males and females in the 5,000 and 10,000 ppm groups. In the 2,000 ppm groups, similar liver neoplasms were present in 63% of the males and in 83% of the females. Of the hepatocellular carcinomas in the 5,000 and 10,000 ppm groups of males and females, 31% to 49% were metastatic to the lungs or other sites. Increases in the incidences of foci of hepatocellular alteration (basophilic, eosinophilic, and clear cell) and pigmentation of the liver were also observed in exposed groups of males and females. Adenomatous polyps (adenoma) of the large intestine were present in six 10,000 ppm males at the 15-month interim evaluation. Incidences of adenomatous polyp (adenoma) and carcinoma of the large intestine were significantly increased in exposed groups of males and females after 2 years; multiple benign and malignant intestinal neoplasms were observed in many of these rats. In the kidney, incidences of renal tubule adenoma and carcinoma were significantly increased in exposed groups of males and females after 2 years. Renal tubule adenomas were present in two 10,000 ppm males at 15 months. There were also chemical-related increases in the incidences and severities of renal tubule epithelial hyperplasia, pigmentation, and transitional cell hyperplasia in the kidney of males and females. Hyaline droplet accumulation was present in all exposed male rats at 9 months. Incidences of transitional cell papilloma and carcinoma of the urinary bladder were increased at 2 years in males and females in the 10,000 ppm groups. Transitional cell hyperplasia was observed in exposed males and females at the 15-month interim evaluation. Other nonneoplastic lesions observed in the urinary bladder at 2 years included metaplasia of the transitional epithelium and submucosal stromal tissue. In the forestomach, the incidences and severities of inflammation, ulceration, hyperkeratosis, and hyperplasia of the squamous mucosa were increased in all exposed groups of males and females at 2 years, but not at the 9- or 15-month interim evaluations. In exposed males and females, the incidences of mononuclear cell leukemia were significantly decreased. The incidences of atrophy of the seminal vesicle were increased in exposed male rats in the 2-year study. Stop-Exposure Evaluation in Rats Groups of 40 male and 40 female rats were given 20,000 ppm 1-amino-2,4-dibromoanthraquinone in feed for 9 or 15 months. At 9 months, 10 males and 10 females were evaluated for histopathology (9-month interim evaluation groups). After 9 months of exposure, an additional 10 males and 10 females were fed control diet until the end of the 15-month evaluation (9-month stop-exposure groups), and 20 males and 20 females continued to receive 20,000 ppm 1-amino-2,4-dibromoanthraquinone until the end of the evaluation (15-month exposure groups). The approximate daily consumption of 1-amino-2,4-dibromoanthraquinone was 1,335 mg/kg for males and 1,790 mg/kg for females in the 9-month stop-exposure groups and 1,115 mg/kg for males and 1,435 mg/kg for females in the 15-month exposure groups. Survival was similar among groups except for the females in the 15-month exposure group; the survival of this group was lower than that of the controls. Lower mean body weights were related to increased exposure duration. The mean body weights of exposed males were 76% to 82% that of controls, and the mean body weights of exposed females were 73% to 84% that of controls. For the stop-exposure evaluation, similar chemical-related neoplasms and nonneoplastic lesions were observed in the same sites as in the 2-year study: liver, large intestine, kidney, urinary bladder, and forestomach. After 9 months of dietary exposure to a concentration of 20,000 ppm 1-amino-2,4-dibromoanthraquinone, hepatocellular adenoma and carcinoma occurred in males and females. Nonneoplastic chemical-related lesions in the liver of exposed rats included pigmentation, focal hepatocellular alteration, and bile duct hyperplasia. Neoplasms at other sites in males included one adenomatous polyp (adenoma) in the large intestine and one transitional cell papilloma in the urinary bladder. Hyaline droplet accumulation was present in the kidney of exposed males at 9 months. In the stop-exposure groups examined at 15 months, hepatocellular adenoma and carcinoma were present in most males and females. Adenomatous polyp (adenoma) of the colon, renal tubule cell adenoma, and urinary bladder transitional cell papilloma and carcinoma also occurred in males and females. Nonneoplastic chemical-related lesions included foci of hepatocellular alteration in the liver and hyperplasia of the renal tubule epithelium and urinary bladder transitional epithelium. Hyperplasia, hyperkeratosis, inflammation, and ulceration were observed in the forestomach of some male and female rats continuously exposed for 15 months. 2-YEAR STUDY IN MICE: Groups of 60 male and 60 female mice were given 0, 10,000, or 20,000 ppm 1-amino-2,4-dibromoanthraquinone in feed for 104 weeks. The daily compound consumption was approximately 1,690 or 3,470 mg 1-amino-2,4-dibromoanthraquinone/kg body weight for males and 1,950 or 4,350 mg/kg for females. Ten animals from each group were evaluated for histopathology at 15 months. Survival, Body Weights, Feed Consumption, and Clinical Findings In the 2-year study, survival of exposed males was significantly lower than that of the controls. Survival of exposed females was similar to that of the controls. The final mean body weights of exposed males were 83% to 85% that of controls, and the final mean body weights of exposed females were 81% to 86% that of controls. Feed consumption by exposed groups was generally similar to that by controls. Discoloration of the fur, urine, and feces was observed in all exposed groups. Pathology Findings In the 2-year study, 1-amino-2,4-dibromoanthraquinone was associated with significant chemical-related increases in the incidences of benign and malignant neoplasms in the liver, forestomach, and lung of males and females. Incidences of hepatocellular adenoma and carcinoma were increased in exposed groups at the 15-month interim evaluation and at 2 years. At 2 years, there were significant increases in the incidences of multiple hepatocellular adenoma and carcinoma in males and females and in the incidences of hepatoblastoma in males. Centrilobular hypertrophy of hepatocytes in males and foci of hepatocellular alteration and pigmentation in the liver of males and females were also chemical-related changes. Sqamous cell papilloma of the forestomach mucosa occurred in 10,000 ppm females and 20,000 ppm males and females at the 15-month interim evaluation, and the incidences of squamous cell papilloma and carcinoma were significantly increased in exposed groups of males and females at 2 years. Chemical-related hyperplasia of forestomach epithelium was also present at 15 months and at 2 years. Alveolar/bronchiolar adenomas were present only in the exposed groups of males and females at 15 months, and the incidences of alveolar/bronchiolar adenoma were significantly increased in exposed males and females at 2 years. The incidences of multiple alveolar/bronchiolar adenomas were also increased in exposed males. In the kidney, pigmentation was present in the renal tubules of most mice after 2 years of exposure. DISPOSITION AND METABOLISM STUDIES: Adult male F344/N rats were given [14C]-labeled 1-amino-2,4-dibromoanthraquinone as a single intravenous dose of 0.4 mg/kg body weight or as a single oral dose of 2, 23, 118, 814, or 1,473 mg/kg. A 6-hour bile cannulation study was also performed. From day 0 through day 3 after intravenous administration, about 50% of the 14C was excreted in the feces, 15% in the urine, and 6% in expired air. Unmetabolized 1-amino-2,4-dibromoanthraquinone accounted for less than 3% of the excreted 14C after intravenous administration. For oral doses administered, the amount of the dose that was absorbed fit the equation: absorbed dose = 6.6 x log(dose). After intravenous administration, the metabolites of 1-amino-2,4-dibromoanthraquinone in blood were primarily in the plasma fraction (blood:plasma ratio of approximately 0.5:1). The highest concentrations of 14C in tissues 15 minutes after intravenous dosing were in excretory organs, lung, kidney, small intestine, liver, adipose tissue, and adrenal gland. GENETIC TOXICOLOGY: 1-Amino-2,4-dibromoanthraquinone was mutagenic in Salmonella typhimurium strains TA98 and TA1537 in the absence of S9; with S9, an equivocal response was observed in TA1537. 1-Amino-2,4-dibromoanthraquinone resulted in an equivocal response in TA100 with and without S9, and no mutagenic activity was detected with strain TA1535. In cultured Chinese hamster ovary cells, 1-amino-2,4-dibromoanthraquinone induced sister chromatid exchanges with and without S9; chromosomal aberrations were induced in the absence of S9. CONCLUSIONS: Under the conditions of these 2-year feed studies, there was clear evidence of carcinogenic activity of 1-amino-2,4-dibromoanthraquinone in male and female F344/N rats based on increased incidences of neoplasms in the liver, large intestine, kidney, and urinary bladder. There was clear evidence of carcinogenic activity of 1-amino-2,4-dibromoanthraquinone in male and female B6C3F1 mice based on increased incidences of neoplasms in the liver, forestomach, and lung. Exposure of male and female rats to 1-amino-2,4-dibromoanthraquinone for 2 years was associated with basophilic focus (males only), clear cell focus, eosinophilic focus, and pigmentation in the liver; renal tubule hyperplasia, renal tubule pigmentation, and transitional cell hyperplasia in the kidney; transitional cell hyperplasia, squamous metaplasia, and stromal metaplasia (females only) in the urinary bladder; squamous hyperplasia, hyperkeratosis, ulceration, and inflammation of the forestomach mucosa; and seminal vesicle atrophy. Exposure of male and female mice to 1-amino-2,4-dibromoanthraquinone for 2 years was associated with centrilobular hepatocellular hypertrophy (males only), basophilic focus, clear cell focus (females only), eosinophilic focus, and pigmentation in the liver; pigmentation in the kidney; and hyperplasia, basal cell hyperplasia, hyperkeratosis, and inflammation of the forestomach mucosa. Synonym: ADBAQ
1-氨基-2,4-二溴蒽醌是一种蒽醌衍生的还原染料,属于一类可浸渍到纺织纤维中的不溶性染料。选择了五种具有代表性且结构多样的蒽醌衍生染料以及母体化合物蒽醌,进行国家毒理学计划(NTP)的毒理学和致癌性评估。与联苯胺染料计划类似,选择这些还原染料的基本原理是生成足够的毒理学数据,以便对该类中的其他化学品进行更可靠的致癌性预测,从而消除或减少对每种蒽醌染料进行研究的必要性。1-氨基-2,4-二溴蒽醌是该组中最后一个被研究的蒽醌衍生染料。将雄性和雌性F344/N大鼠以及B6C3F1小鼠分组,分别暴露于1-氨基-2,4-二溴蒽醌(纯度87%至97%)13周、9个月、15个月或24个月。由于预计1-氨基-2,4-二溴蒽醌具有致癌性,这些研究旨在评估肿瘤进展和消退的可能性。在雄性F344/N大鼠中进行了吸收和排泄研究。使用鼠伤寒沙门氏菌和培养的中国仓鼠卵巢细胞进行体外遗传毒性测定。进行了广泛的化学分析,以鉴定和表征这些研究中使用的1-氨基-2,4-二溴蒽醌的杂质。
大鼠13周研究:将10只雄性和10只雌性大鼠分为几组,在饲料中给予0、2500、5000、10000、25000或50000 ppm的1-氨基-2,4-二溴蒽醌,持续13周。这些剂量水平相当于雄性每天约150至3200 mg 1-氨基-2,4-二溴蒽醌/千克体重,雌性每天约170至3200 mg/千克体重。化学相关死亡率仅限于50000 ppm组中的一只雄性和一只雌性。所有暴露组大鼠的最终平均体重和体重增加均显著低于对照组。在整个研究过程中,所有暴露组的饲料消耗量均低于对照组,并且通常随着暴露浓度增加而减少。在所有暴露组中均观察到皮毛和尾巴出现粉红 - 红色染色。所有暴露组的绝对肝脏重量和相对肝脏重量通常显著高于对照组。雄性和雌性大鼠的肝脏、肾脏和脾脏中均出现化学相关病变。肝脏中的非肿瘤性病变包括肝细胞改变灶、弥漫性肝细胞肥大(细胞肿大)、肝细胞胞质空泡化、胆管增生、炎症和色素沉着。这些差异主要在25000和50000 ppm的雄性和雌性组中观察到;25000和50000 ppm组中胆管的增殖性病变(增生、纤维化和坏死性胆管炎)在形态学上与描述为胆管纤维化的病变一致。所有暴露组大鼠的肾小管上皮均有色素沉着;部分暴露大鼠的肾小管上皮中也出现核肿大(核仁增大)。2500、5000、10000和25000 ppm雄性大鼠的肾小管上皮细胞质和管腔中出现透明滴积累。与对照组相比,暴露组雄性和雌性大鼠脾脏的造血发生率增加。
小鼠13周研究:将10只雄性和10只雌性小鼠分为几组,在饲料中给予0、2500、5000、10000、25000或50000 ppm的1-氨基-2,4-二溴蒽醌,持续13周。这些剂量水平相当于雄性每天约500至10600 mg 1-氨基-2,4-二溴蒽醌/千克体重,雌性每天约660至11700 mg/千克体重。未出现化学相关死亡。暴露组的饲料消耗量和最终平均体重与对照组相似。在所有暴露组中均观察到皮毛出现红色染色。除2500 ppm雄性大鼠的绝对肝脏重量外,暴露组的绝对肝脏重量和相对肝脏重量均大于对照组。25000和50000 ppm雄性大鼠的绝对肾脏重量和相对肾脏重量低于对照组。化学相关病变仅限于雄性肝脏,在所有暴露浓度下均有肝细胞色素沉着,在10000、25000和50000 ppm时有小叶中央肝细胞肥大。25000 ppm组的一只雌性和50000 ppm组的一只雌性肝脏中存在最小量色素。
将70只雄性和70只雌性大鼠分为几组,在饲料中给予0、5000或10000 ppm的1-氨基-2,4-二溴蒽醌,持续103周。此外,将50只雄性和50只雌性大鼠分为几组,在饲料中给予2000 ppm的1-氨基-2,4-二溴蒽醌,持续104周。这些暴露浓度相当于雄性约90、240或490 mg 1-氨基-2,4-二溴蒽醌/千克体重,雌性约110、285或600 mg/千克体重。每组10只动物在9个月时进行组织病理学评估。来自0 ppm和10000 ppm组的另外每组10只动物在15个月时进行组织病理学评估。
生存、体重、饲料消耗和临床发现:在两年研究中,10000 ppm雄性和雌性大鼠的生存率显著低于对照组。2000和5000 ppm组的生存率与对照组相似。在研究的最后一年,暴露雄性大鼠的平均体重为对照组的80%至91%,暴露雌性大鼠的平均体重为对照组的67%至84%。暴露组的饲料消耗量通常相似,但低于对照组。所有暴露的雄性和雌性组的皮毛和尿液均变色。
在两年研究中,1-氨基-2,4-二溴蒽醌与雄性和雌性肝脏、大肠、肾脏和膀胱中良性和恶性肿瘤发生率的显著化学相关增加有关。化学相关的非肿瘤性增殖和退行性病变发生在雄性和雌性的肝脏、肾脏、膀胱和前胃。在中期9个月评估时,雄性和雌性肝脏中肝细胞改变灶和色素沉着的发生率增加,一只5000 ppm雄性大鼠出现肝细胞腺瘤。在中期15个月评估时,10000 ppm组的所有雄性和9只雌性出现肝细胞腺瘤或癌(合并)。到两年研究结束时,5000和10000 ppm组的雄性和雌性中观察到肝细胞腺瘤、癌、胆管瘤或胆管癌。在2000 ppm组中,63%的雄性和83%的雌性出现类似的肝脏肿瘤。在5000和10000 ppm组的雄性和雌性肝细胞癌中,31%至49%转移至肺部或其他部位。暴露组的雄性和雌性肝脏中肝细胞改变灶(嗜碱性、嗜酸性和透明细胞)和色素沉着的发生率也增加。在中期15个月评估时,10000 ppm组的6只雄性出现大肠腺瘤性息肉(腺瘤)。两年后,暴露组的雄性和雌性大肠腺瘤性息肉(腺瘤)和癌的发生率显著增加;许多这些大鼠中观察到多个良性和恶性肠道肿瘤。在肾脏中,两年后暴露组的雄性和雌性肾小管腺瘤和癌的发生率显著增加。15个月时,两只10000 ppm雄性大鼠出现肾小管腺瘤。雄性和雌性肾脏中肾小管上皮增生、色素沉着和移行细胞增生的发生率和严重程度也有化学相关增加。9个月时,所有暴露雄性大鼠均出现透明滴积累。10000 ppm组的雄性和雌性在两年时膀胱移行细胞乳头状瘤和癌的发生率增加。在中期15个月评估时,暴露的雄性和雌性出现移行细胞增生。两年时在膀胱中观察到的其他非肿瘤性病变包括移行上皮化生和黏膜下基质组织化生。在前胃中,两年时所有暴露组的雄性和雌性炎症、溃疡、角化过度和鳞状黏膜增生的发生率和严重程度增加,但在中期9个月或15个月评估时未出现。在暴露的雄性和雌性中,单核细胞白血病的发生率显著降低。在两年研究中,暴露雄性大鼠精囊萎缩的发生率增加。
将40只雄性和40只雌性大鼠分为几组,在饲料中给予20000 ppm的1-氨基-2,4-二溴蒽醌,持续9个月或15个月。在9个月时,对10只雄性和10只雌性进行组织病理学评估(9个月中期评估组)。暴露9个月后,另外10只雄性和10只雌性改喂对照饲料直至15个月评估结束(9个月停止暴露组),20只雄性和20只雌性继续接受20000 ppm的1-氨基-2,4-二溴蒽醌直至评估结束(15个月暴露组)。9个月停止暴露组中,雄性1-氨基-2,4-二溴蒽醌的每日摄入量约为1335 mg/千克,雌性约为1790 mg/千克;15个月暴露组中,雄性约为1115 mg/千克,雌性约为1435 mg/千克。除15个月暴露组的雌性外,各组生存率相似;该组生存率低于对照组。平均体重较低与暴露持续时间增加有关。暴露雄性大鼠的平均体重为对照组的76%至82%,暴露雌性大鼠的平均体重为对照组的73%至84%。对于停止暴露评估,在与两年研究相同的部位观察到类似的化学相关肿瘤和非肿瘤性病变:肝脏、大肠、肾脏、膀胱和前胃。在饮食中暴露于浓度为20000 ppm的1-氨基-2,4-二溴蒽醌9个月后,雄性和雌性出现肝细胞腺瘤和癌。暴露大鼠肝脏中的非肿瘤性化学相关病变包括色素沉着、局灶性肝细胞改变和胆管增生。雄性其他部位的肿瘤包括大肠中的一个腺瘤性息肉(腺瘤)和膀胱中的一个移行细胞乳头状瘤。9个月时,暴露雄性大鼠的肾脏出现透明滴积累。在15个月检查的停止暴露组中,大多数雄性和雌性出现肝细胞腺瘤和癌。雄性和雌性还出现结肠腺瘤性息肉(腺瘤)、肾小管细胞腺瘤以及膀胱移行细胞乳头状瘤和癌。非肿瘤性化学相关病变包括肝脏中的肝细胞改变灶以及肾小管上皮和膀胱移行上皮增生。在连续暴露15个月的部分雄性和雌性大鼠的前胃中观察到增生、角化过度、炎症和溃疡。
将60只雄性和60只雌性小鼠分为几组,在饲料中给予0、10000或20000 ppm的1-氨基-2,4-二溴蒽醌,持续104周。雄性和雌性的每日化合物摄入量分别约为1690或3470 mg 1-氨基-2,4-二溴蒽醌/千克体重以及1950或4350 mg/千克体重。每组10只动物在15个月时进行组织病理学评估。
生存、体重、饲料消耗和临床发现:在两年研究中,暴露雄性大鼠的生存率显著低于对照组。暴露雌性大鼠的生存率与对照组相似。暴露雄性大鼠的最终平均体重为对照组的83%至85%,暴露雌性大鼠的最终平均体重为对照组的81%至86%。暴露组的饲料消耗量通常与对照组相似。所有暴露组均观察到皮毛、尿液和粪便变色。
在两年研究中,1-氨基-2,4-二溴蒽醌与雄性和雌性肝脏、前胃和肺部良性和恶性肿瘤发生率的显著化学相关增加有关。在中期15个月评估和两年时,暴露组肝细胞腺瘤和癌的发生率增加。在两年时雄性和雌性多发性肝细胞腺瘤和癌的发生率以及雄性肝母细胞瘤的发生率显著增加。雄性肝细胞小叶中央肥大以及雄性和雌性肝脏中肝细胞改变灶和色素沉着也是化学相关变化。在中期15个月评估时,10000 ppm雌性和20000 ppm雄性和雌性出现前胃黏膜鳞状细胞乳头状瘤,在两年时暴露组的雄性和雌性鳞状细胞乳头状瘤和癌的发生率显著增加。在15个月和两年时也出现化学相关的前胃上皮增生。仅在中期15个月时暴露组的雄性和雌性出现肺泡/细支气管腺瘤,在两年时暴露的雄性和雌性肺泡/细支气管腺瘤的发生率显著增加。暴露雄性中多发性肺泡/细支气管腺瘤的发生率也增加。在肾脏中,暴露两年后大多数小鼠的肾小管出现色素沉着。
成年雄性F344/N大鼠静脉注射给予0.4 mg/千克体重的[¹⁴C]标记1-氨基-2,4-二溴蒽醌单剂量,或口服给予2、23、118、814或1473 mg/千克体重的单剂量。还进行了一项6小时的胆汁插管研究。从静脉给药后第0天至第3天,约50%的¹⁴C经粪便排泄,15%经尿液排泄,6%经呼出空气排泄。静脉给药后,未代谢的1-氨基-2,4-二溴蒽醌占排泄¹⁴C的比例不到3%。对于口服给药剂量,吸收剂量符合方程:吸收剂量 =